Document is current
Any future updates will be listed below
-
Authors
Brudno, Jennifer N. https://orcid.org/0000-0002-7904-8415
Kochenderfer, James N.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC011417 02)
Gilead Sciences (CRADA 3019)
CRADA with Kite Pharma, a Gilead company
- License Information
-
More Information
Article History
Received: 24 March 2023
Revised: 29 June 2023
Accepted: 10 July 2023
First Online: 15 July 2023
Competing interests
: JNB: scientific advisory board for Kyverna Therapeutics, Inc. (unpaid position). JNK: Royalties from Kite, a Gilead Company, Celgene/Bristol Myers Squibb, and Kyverna Therapeutics, Inc. Research funding from Kite, a Gilead Company, and Celgene/Bristol Myers Squibb.
: Written informed consent was obtained from all clinical trial participants. The study was approved by the National Institutes of Health IRB.
